

World Health Organization Update

Irena Prat

**Department of Essential Medicines and Health Products
Prequalification Team**

With thanks to Josée Hansen for her contribution



**World Health
Organization**

Presentation Layout



- Prequalification of IVDs
- Model Regulatory Framework for medical devices
- WHO NRA assessment tool



PREQUALIFICATION OF IN VITRO DIAGNOSTICS PROGRAMME



WHO's work in IVDs area: background



Millennium development goals

The United Nations Millennium Development Goals are eight goals that all 191 UN Member States have agreed to try to achieve by the year 2015.

- 4. to reduce child mortality;
- 5. to improve maternal health;
- 6. to combat HIV/AIDS, malaria, and other diseases;



Universal health coverage

Universal coverage is based on the WHO constitution of 1948 declaring health a fundamental human right and on the Health for All agenda set by the Alma-Ata declaration in 1978.

For a community or country to achieve universal health coverage, several factors must be in place, including:

Access to essential medicines and technologies to diagnose and treat medical problems.



Role of WHO prequalification

- > Facilitate access to safe, appropriate priority IVDs, medicines and vaccines
- > Support two of WHO's six core functions
 - > setting norms & standard/promoting their implementation
 - > providing technical support, catalyzing change & building institutional capacity
- > Contribute to achieving four of WHO's impact goals
 - > reduce under-five mortality
 - > reduce maternal mortality
 - > reduce the number of people dying from AIDS, tuberculosis and malaria
 - > eradicate polio



Prequalification of in vitro diagnostics programme

- > Includes three components:
 - > Review of a product dossier;
 - > Performance evaluation, including operational characteristics; and
 - > Manufacturing site(s) inspection.
- > Looks into quality, safety and performance through dossier review, performance evaluation and inspection
 - > Dossier: safety and performance
 - > Performance evaluation: performance
 - > Inspections: quality



Reference documents

PQDx is aligned with best international practice for IVDs

- ISO (and EN) standards: QMS, risk mgt, stability, labelling, perf. evaluations, etc.
- GHTF/IMDRF guidance: STED, MDSAP, labelling, EPs, PMS
- CLSI guidance: stability, V&V,
- NRAs: FDA, EU



What does PQ do differently to GHTF/IMDRF

Requirements are based on the same set of standards – PQ is aligned with internationally accepted practice BUT

Assess products' regulatory versions intended for the global market


- Where a stringently reviewed versions exist, they are often not supplied to the global market – RoW versions differ from stringently assessed version in Mx site, QC, labelling, key suppliers, composition, intended use etc.

Review aspects of particular relevance for resource-limited settings


- Risk assessment, stability, flex studies, labelling, training and support network
- Take into account environment and user skills



Post-prequalification phase




PQ in a regulatory framework



Future developments

- > Product dossier:
 - > 3 sample dossiers (VL, EID and HIVST)
 - > several guidance documents to support dossier submissions
 - > TGS1 Reference documents
 - > TGS2 Stability studies
 - > TGS3 Principles for performance studies
 - > TGS4 Sample dossiers
 - > TGS5 Product specific guidance
 - > TGS6 IFU
 - > TGS7 Flex studies
 - > TGS8 Specimen types
 - > TGS9 Test method validation
 - > IMDRF ToC (more granularity than STED)
- > Inspections:
 - > guidance documents
 - > TGS10 Quality control principles
 - > TGS11 Outsourcing and supplier mgt



Prequalification of in vitro diagnostics programme

- > Lab evaluations:
 - > WHO has been supporting studies through WHO collaborating labs;
 - > new mechanism being designed to capture efforts from various partners and join forces with other organizations supporting IVDs QA

- > Joint assessments
 - > Capacity building mechanism to strengthen NRAs and provide insight into PQDx assessment
 - > Sessions for regulators

- > PQ framework expansion to HPV

- > Collaborative procedure



MODEL REGULATORY FRAMEWORK



Purpose

- A Model Regulatory Framework for medical devices including IVD's with global input and reflecting a modular approach in regulating medical devices
 - How to begin regulating?
 - What to regulate: harmonized definitions and guiding principles
 - How to regulate; stepwise development and implementation
 - When to regulate: stepwise approach
- Regional workshops and capacity building
- Parallel to the NRA assessment tool for medical devices



Justification

- Medical products should be safe and effective
- Resolution WHA 67.20 on Regulatory System Strengthening for medical products
- Member states request for support on regulatory system strengthening
- Increasing importance of medical devices: regulating an existing market
- Globalizing world
- Lack of regulation in many member states
(<http://apps.who.int/medicinedocs/documents/s21456en/s21456en.pdf>)



Publications

- A Model Regulatory Program for Medical Devices: An International Guide 2001 PAHO
- Medical Device Regulations: Global overview and guiding principles 2003 WHO
- The GHTF Regulatory Model 2011
- AHWP Playbook for implementation of medical device regulatory frameworks 2014



What's new?

- Working group is engaged in the development of the Model Regulatory Framework for medical devices
- Public consultations to generate feedback and input
- Adoption by Expert Committees






Where we are now

- Definition of a medical device and IVD as a medical device
 - GHTF definitions
- Life cycle of a medical device
- Stepwise approach: three levels





Stepwise Approach

Basic Elements

- Establishment of Essential Principles of Safety and Performance
- Issuing guidance documents on regulatory requirements
- Registration of manufacturers, importers and distributors
- Listing of medical devices placed on the market
- Import controls
- Market surveillance, supply chain control, traceability
- Labelling and instruction for use controls
- Serious adverse events, recalls, FSCAs or withdrawal from market in exchange with other NRAs
- Provision for exemptions from regulatory requirements e.g. donations and humanitarian use.
- Enforce regulations



Stepwise Approach

Intermediate Elements

- QMS including good record keeping requirements
- Administrative controls for reliance
- Recognition and adoption of international standards
- Control of advertising
- Adverse event reporting within a vigilance system*

Full Implementation

- Premarket decision on compliance of medical device with essential principles (with reliance and/or review)
- Notification of clinical investigations and/or serious deviations and/or adverse events
- QMS auditing (by reliance and/or by auditing)
- Appoint and oversee CABs
- Establishment of a test laboratory function (national or regional or by reliance)
- Mechanism for analyses and dissemination of alerts on medical devices (national, regional, international)



NRA ASSESSMENT TOOL



Objective of NRA assessment

Strengthen the regulatory *systems* for all medical products to assure the quality, safety and efficacy of all medical products




History

- Vaccines since 1997
 - NRAs assessed
- Medicines since 2001
 - NRAs assessed
- Medical devices
 - WHO NRA tool for medical devices developed 2013.
 - PAHO tool for medical devices: 2012-2015. Piloted in 5 countries




WHO Global Assessment Tool 2015

National Regulatory System (NRS) and Functions (NRF)



Harmonized tool : Phase 1 and 2



Policy for NRA Assessment medical devices

- Focus on member states with no or limited regulatory system for medical devices in place
- Focus on basic level of regulation
- Some basic regulatory system has to be in place

Next steps and time line

- First draft of the Model Regulatory Framework for medical devices January 2015
- Public Consultations in April and August
- In parallel: regional awareness workshops
- Under development: self assessments and capacity building for regulating medical devices at basic level
- In parallel: NRA assessment if applicable



**Thank you very much for your
attention.**



**World Health
Organization**